

Unresectable NSCLC: no patients left behind

FRIDAY 1 APRIL 2022 | 12:45–14:15 (CEST)

FORUM HALL, PRAGUE CONGRESS CENTRE, PRAGUE, CZECH REPUBLIC

Introduction to the faculty and overview of meeting objectives

Julien Mazieres (Chair)

Different treatment approaches in unresectable Stage III NSCLC

Julien Mazieres (Chair)

Advancements in radiation modalities in unresectable Stage III NSCLC

Andrea Filippi

Hard-to-treat patient populations in unresectable Stage III NSCLC

Andreas Rimner

Case study presentation: hard-to-treat patient populations – the need for an MDT approach

Dirk De Ruyscher

Future directions – the treatment paradigm for unresectable Stage III NSCLC

Silvia Formenti

Live Q&A/discussion

All faculty



Julien Mazieres

Toulouse University Hospital,
Paul Sabatier University,
France



Andrea Filippi

University of Pavia,
Italy



Andreas Rimner

Memorial Sloan Kettering
Cancer Center,
US



Dirk De Ruyscher

Maastricht University
Medical Centre,
The Netherlands



Silvia Formenti

Weill Cornell Medical
College,
US

AstraZeneca's Commitment to Sustainability



\$19 million

invested in
environmental efficiency
projects in 2020
(NRRGG fund)



CPD A Lists

One of three companies
worldwide to achieve
double A listing for
Climate Change and
Water Security for five
consecutive years



89% of our power

is sourced or
generated from
renewable sources



100% of API

(Active Pharmaceutical
Ingredient) discharges
from AstraZeneca sites
were assessed as safe



20% reduction

in our water use
since 2015



**100% of our
vehicles**

will be electric
by 2025



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website

This is a promotional symposium, funded and organised by AstraZeneca

VPM ID: CZ-2980 | Date of preparation: March 2022

AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK